Financials and Corporate

Upcoming investor conferences

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at four upcoming investor conferences in Q1 2017, where Innate Pharma’s management team...

Third quarter 2016 report

Cash, cash equivalents and financial assets amounting to €239.6 million [1] Continued progress with key clinical trials Safety data for lirilumab in combination in Phase I studies presented at the...